MedTrace Logo

A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

NCT00163098 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2006-10-13

No results posted yet for this study

Summary

A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

UK-369,003

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2005-12-31

Countries

  • Argentina
  • Australia
  • Germany
  • India
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00163098 on ClinicalTrials.gov